The Discovery Desk: Ono Pharmaceutical Embeds Phylo's Biomni Lab Across Its Scientists
Ono Pharmaceutical deploys Phylo's Biomni Lab agentic AI platform across its full discovery organization — a platform bet, not an asset-specific deal.
Large pharma has spent a decade buying point solutions — target ID here, molecular design there. Ono Pharmaceutical's July 28, 2026 deal with Phylo is structurally different: it deploys an agentic AI platform across the entire discovery organization, not around a single asset.
The deal
Ono Pharmaceutical Co., Ltd. (TYO: 4528) and Phylo, Inc. announced a collaboration bringing Biomni Lab — Phylo's agentic AI platform for biomedical research — to Ono's drug discovery scientists.
Financial terms were not disclosed. The agreement is a platform deployment, not a co-development deal around named drug candidates.
What Biomni Lab does
Phylo describes Biomni Lab as an Integrated Biology Environment where scientists collaborate with AI agents on end-to-end workflows:
- Synthesizing experimental history
- Reasoning over internal proprietary datasets
- Designing experiments
- Executing computational biology tasks
Ono contributes its accumulated discovery data and domain expertise across oncology, immunology & inflammation, and neurology — the therapeutic areas where the 300-year-old Osaka company built its reputation, including the PD-1 antibody nivolumab (Opdivo).
Executive quotes (on record)
Seishi Katsumata, Corporate Officer / Executive Vice President, Discovery & Research at Ono:
"We believe AI will become a core capability for drug discovery. With patients waiting for new medicines, there is an urgent need to help scientists move faster without compromising scientific rigor. Biomni Lab stood out because our researchers quickly adopted it and saw its potential to accelerate everyday discovery."
Kexin Huang, Ph.D., Co-Founder & CEO of Phylo:
"We believe drug discovery can be faster and more efficient with scientists working alongside AI agents. Ono's discovery leadership across oncology, immunology & inflammation, and neurology makes them an ideal partner."
Phylo's trajectory
Phylo launched Biomni Lab commercially in February 2026 following a $13.5 million seed round co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund. The platform traces to an open-source Stanford project adopted by 7,000+ laboratories before commercialization.
Prior deployments cited publicly include work with Ginkgo Bioworks and agentic clinical-trial emulation with Mount Sinai researchers.
Why this deal pattern matters
Pharma's agentic-AI wave is splitting into two lanes:
- Asset-specific partnerships — AI applied to one molecule or target class
- Organizational infrastructure — AI embedded in how every discovery scientist works
Ono chose the second. The hard part, as Phylo's own benchmarks suggest, is converting decades of tacit lab practice into procedures agents can follow reliably — the step that separates demo adoption from production science.